Jeffrey Cohen, MD

October 28, 2022

The neurologist in the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic, shares more on his late breaker presentation from the 38th ECTRIMS conference. [WATCH TIME: 4 minutes]

June 07, 2022

Jeffrey Cohen, MD, spoke about the topic of his CMSC Presidential Lecture at the 2022 annual meeting, stem cell transplantation in multiple sclerosis, and what questions remain unanswered in this realm of treatment.

June 06, 2022

Jeffrey Cohen, MD, shared his perspective on the current use and study of stem cells for the treatment of multiple sclerosis, which he covered in the CMSC Presidential Lecture at the 2022 annual meeting.

February 24, 2022

The professor of neurology at Cleveland Clinic and president of ACTRIMS noted his excitement for this year’s Forum, which will feature presentations on a variety of topics in the field of multiple sclerosis. [WATCH TIME: 2 minutes]

February 11, 2022

Jeffrey Cohen, MD, director, Mellen Center for MS Treatment and Research, Cleveland Clinic; and president, ACTRIMS, discussed what he is looking forward to at the 2022 ACTRIMS Forum, as well as the overarching themes of the meeting. [WATCH TIME: 2 minutes]

November 29, 2021

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the possibility of using multiple DMTs to combat the effects of MS. [WATCH TIME: 3 minutes]

November 22, 2021

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed when clinicians should anticipate new therapies to treat progressive MS. [WATCH TIME: 2 minutes]

October 21, 2021

Ahmed Obeidat, MD, PhD; Jeffrey Cohen, MD; and Erin Longbrake, MD, PhD discuss the evolution of fellowship training for multiple sclerosis specialists.

October 14, 2021

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic provided context on whether efficacy outcomes should be weighed more than mechanistic action when evaluating MSC-NTF cell therapies. [WATCH TIME: 3 minutes]

October 13, 2021

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the use of MSC-NTF cells in progressive MS and the data backing this approach. [WATCH TIME: 3 minutes]